[HTML][HTML] Micron-sized and submicron-sized aerosol deposition in a new ex vivo preclinical model
Background The knowledge of where particles deposit in the respiratory tract is crucial for
understanding the health effects associated with inhaled drug particles. Method An ex vivo …
understanding the health effects associated with inhaled drug particles. Method An ex vivo …
[HTML][HTML] Management of neuroendocrine neoplasms: conformity with guidelines in and outside a center of excellence
C Morin, KM Benedetto, A Deville, L Milot… - Endocrine …, 2022 - ec.bioscientifica.com
… Agathe Deville Agathe Deville Hospices Civils de Lyon, Hôpital Louis Pradel, Médecine
Nucléaire, Bron, France … Search for other papers by Agathe Deville in …
Nucléaire, Bron, France … Search for other papers by Agathe Deville in …
[HTML][HTML] Proof of concept of the radiosensitizing effect of gadolinium oxide nanoparticles in cell spheroids and a tumor-implanted murine model of chondrosarcoma
MT Aloy, JS Boumedine, A Deville, D Kryza… - International Journal …, 2022 - ncbi.nlm.nih.gov
Purpose Chondrosarcomas (CHSs), which represent 20% of primary bone tumors in adults,
are mostly resistant to radio-and chemotherapy. It is therefore essential that new therapeutic …
are mostly resistant to radio-and chemotherapy. It is therefore essential that new therapeutic …
[HTML][HTML] Amino Acid Solutions for 177Lu-Oxodotreotide Premedication: A Tolerance Study
P Courault, A Deville, V Habouzit, F Gervais, C Bolot… - Cancers, 2022 - mdpi.com
Simple Summary [ 177 Lu]oxodotreotide (Lutathera ® ) was approved by the European
Medical Agency in 2017 and the Food and Drug Administration in 2018 for the treatment of …
Medical Agency in 2017 and the Food and Drug Administration in 2018 for the treatment of …
Outcome on Mesenteric Mass Response of Small-Intestinal Neuroendocrine Tumors Treated by 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy: The …
…, G Tlili, J Tordo, M Janier, A Deville… - Journal of Nuclear …, 2024 - Soc Nuclear Med
A mesenteric mass (MM), characterized by fibrotic reaction, is present in most small-intestinal
neuroendocrine tumors (SI-NETs). Lu-DOTATATE peptide receptor radionuclide therapy (…
neuroendocrine tumors (SI-NETs). Lu-DOTATATE peptide receptor radionuclide therapy (…
Dosimétrie rénale du 177Lu-Dotatate: mise en place au sein du Groupement hospitalier Est des Hospices Civils de Lyon
V Habouzit, P Tylski, A Deville, C Bournaud - Médecine Nucléaire, 2020 - Elsevier
Introduction Le rein est un des organes à risque du traitement par 177 Lu-Dotatate. La
dosimétrie rénale pourrait jouer un rôle dans l’optimisation du traitement. Nous présentons un …
dosimétrie rénale pourrait jouer un rôle dans l’optimisation du traitement. Nous présentons un …
Peptide Receptor Radionuclide Therapy by 177Lu-DOTATATE of a Secreting Cervical Paraganglioma
A Deville, I Pinigina, L Al Mansour… - Clinical Nuclear …, 2022 - journals.lww.com
A 59-year-old man with a parapharyngeal paraganglioma incidentally discovered on a
cervical swelling was referred to our nuclear medicine department for a morpho-metabolic …
cervical swelling was referred to our nuclear medicine department for a morpho-metabolic …
Unexpected Vertebral Bodies Trapping of 99mTc–Macroaggregated Albumin During Lung Perfusion Scintigraphy in a Patient With Collateral Paravertebral Venous …
M Dietz, S Si-Mohamed, A Deville, J Tordo… - Clinical Nuclear …, 2021 - journals.lww.com
A 35-year-old woman was referred to our nuclear medicine center for a ventilation and
perfusion (VQ) pulmonary scintigraphy to detect pulmonary embolism. She was treated with low-…
perfusion (VQ) pulmonary scintigraphy to detect pulmonary embolism. She was treated with low-…
[PDF][PDF] Research Article Title: Management of neuroendocrine neoplasms: conformity with guidelines in and outside a center of excellence
C Morin, KM Benedetto, A Deville, L Milot… - 2022 - scholar.archive.org
… Carole Morin1, Keo-Morakort Benedetto1, Agathe Deville2,7, Laurent Milot3,8, Aurélie
Theillaumas1, Valérie Hervieu4,7,8, Mathieu Pioche5,8, Gilles Poncet6,7,8, Julien …
Theillaumas1, Valérie Hervieu4,7,8, Mathieu Pioche5,8, Gilles Poncet6,7,8, Julien …
68Ga-PSMA-PET/CT after a non-contributively 18F-Choline PET/CT in patients in biochemical relapse of prostate cancer
…, A Dhomps, C Darcissac, I Morelec, P Got, A Deville… - 2020 - Soc Nuclear Med
1258 Introduction: PSMA PET/CT is a recent nuclear medicine exam, particularly useful in
the management of patients followed for prostate cancer. The aim of this study was to …
the management of patients followed for prostate cancer. The aim of this study was to …